Application of the Reactive Oxygen-Based Cervical Exfoliated Cell Staining Solution in Clinical Cervical Cancer Screening
GAO Fei1,2, LÜ Qiongying2, ZHANG Wei2, XIAO Chengrong3, XIANG Qunying4, LI Lijia1†1. State Key Laboratory of Hybrid Rice / College of Life Sciences, Wuhan University, Wuhan 430072, Hubei, China; 2. Gynecological Department, Zhongnan Hospital of Wuhan University, Wuhan 430072, Hubei, China; 3. Central China Institutes of Biomedical Sciences, Shenzhen 518000, Guangdong, China; 4. Maternity and Child Care Hospital, Wufeng 443400, Hubei, China
We developed a special methylene blue solution for staining of cervix shedding cells based on catalytic oxidizing chromogenic reaction, which shows a potential for cervical cancer cytology screening. We screened a total of 1 922 women for cervical cancer with the special methylene blue staining method and a conventional Pap smear method using cervix shedding cells. Then, the patients with positive indicators of the Pap smear or this special solution staining method were examined by the electron colposcopy and histopathological examination. Staining of cervical exfoliated cells with this reactive oxygen-based special solution showed that the number of positive cases was 140 (7.28%). Among them, 21 cases showed dark green (1.09%), and 119 cases showed purple black (6.19%). The results of the Pap smear method showed that the num-ber of positive cases was 123 (6.40%), of which ASCUS was 105 (5.46%), ASC-H was 5 (0.26%), and LSIL was 9 (0.47%), and HSIL was 4 (0.21%). For cervical exfoliated cell special staining solution for screening cervical intraepithelial neoplasia (CIN-Ⅱ, CIN-Ⅲ) and cervical cancer, sensitivity was 83.33%, specificity was 65.52%, accuracy was 74.29%, missed diagnosis rate was 13.33%, positive coincidence rate was 51.43%, and the negative coincidence rate is 86.67%. Our results proved the value of this method for early screening of cervical cancer through clinical practice in China.
Key words:preliminary screening of cervical cancers; a reactive oxygen-based method for staining of cervix shedding cells; sensitivity; specificity
 Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer [J]. Nature, 2017, 543(7645): 378-384.
 Mezei A K, Armstrong H L, Pedersen H N, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review [J]. Int J Cancer, 2017, 141(3): 437-446.
 Meeusen E, Lim E, Mathivanan S. Secreted tumor antigens-immune biomarkers for diagnosis and therapy [J]. Proteomics, 2017, 17(23-24): 1600442.
 Dasari S, Wudayagiri R, Valluru L. Cervical cancer: Biomarkers for diagnosis and treatment [J]. Clinica Chimica Acta, 2015, 445: 7-11.
 Comparetto C, Borruto F. Cervical cancer screening: A never-ending developing program[J]. World Journal of Clinical Cases, 2015, 3(7): 614-624.
 Tsikouras P, Zervoudis S, Manav B, et al. Cervical cancer: Screening, diagnosis and staging[J]. Journal of Buon, 2016, 21(2): 320-325.
 Di J, Rutherford S, Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China [J]. Asian Pac J Cancer Prev, 2015, 16(17): 7401- 7407.
 Shi J F, Chen J F, Canfell K, et al. Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: A micro-costing study[J]. BMC Health Services Research, 2012, 12: 123.
 Link E M, Blower P J, Costa D C, et al. Early detection of melanoma metastases with radioiodinated methylene blue [J]. European Journal of Nuclear Medicine, 1998, 25(9): 1322-1329.
 Blower P J, Clark K, Link E M. Radioiodinated methylene blue for melanoma targeting: Chemical characterisation and tumour selectivity of labelled components [J]. Nuclear Medicine & Biology, 1997, 24(4): 305-310.
 Gonçalves T L, Erthal F, Corte C L, et al. Involvement of oxidative stress in the pre-malignant and malignant states of cervical cancer in women [J]. Clinical Biochemistry, 2005; 38(12): 1071-1075.
 Wu W S. The signaling mechanism of ROS in tumor progression [J]. Cancer & Metastasis Reviews, 2006, 25(4): 695-705.
 Li L J, Zhang W, Gao F, et al. A Diagnostic Reagent and a Preparation Method for Cervical Cancer Cell Detection [P]. CN: ZL201410804606.0, 2016-12-19.
 Du P L, Wu K S, Fang J Y, et al. Cervical cancer mortality trends in China, 1991-2013, and predictions for the future [J]. Asian Pacific Journal of Cancer Prevention, 2015, 16(15): 6391-6396.
 Goss P E, Strasser-Weippl K, Lee-Bychkovsky B L, et al. Challenges to effective cancer control in China, India, and Russia [J]. The Lancet Oncology, 2014, 15(5):489-538.
 Sunny S, Satyajyoti S, Flora K, et al. Current technologies and recent developments for screening of HPV-associated cervical and oropharyngeal cancers [J]. Cancers, 2016, 8(9): 85.